AstraZeneca’s Lynparza shows promising results in phase 3 ovarian cancer trial

AstraZeneca has reported significant findings from its phase 3 trial, SOLO-2, for its ovarian cancer drug Lynparza (olaparib), demonstrating considerable improvement in survival chances for ... Read More